What we know about COVID-19
Keywords:
coronavirus, 2019-nCoV, COVID-19, SARS-CoV-2Abstract
Introduction: coronaviruses are a large family of viruses that had already been documented as causing colds and serious illnesses such as severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012. On December 2019, in Wuhan City, Hubei Province, China, a new disease caused by a coronavirus belonging to the β-coronavirus family originated, which was later named SARS-CoV-2.Objective: to inform the medical community of the City of Santa Clara, the Province of Villa Clara, Cuba and the world about the published topics that deal with the most relevant aspects of the disease.
Method: a bibliographic review was carried out in different databases, both in English and Spanish.
Conclusions: there is no specific, effective and proven drug for the treatment of COVID-19. The most valuable scientific evidence currently available that works is measures to prevent the spread of this infection.
Downloads
References
1.de Francisco ALM, Perez Canga JL. Coronavirus y riñón. Actualización completa. 9 de junio de 2020. Nefrología al día [Internet]. Barcelona: Sociedad Española de Nefrología; 2020 [citado 25/02/2021]. Disponible en: https://www.nefrologiaaldia.org/es-articulo-coronavirus-rinon-actualizacion-completa-25-305
2.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med [Internet]. 2020 Feb [citado 25/02/2021];382(8):727-733. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092803/. https://dx.doi.org/10.1056/nejmoa2001017
3.Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol [Internet]. 2020 Apr [citado 25/02/2021];5(4):536-544. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095448/. https://dx.doi.org/10.1038/s41564-020-0695-z
4.Frutos R, Serra-Cobo J, Chen T, Devaux CA. COVID-19: Time to exonerate the pangolin from the transmission of SARS-CoV-2 to humans. Infect Genet Evol [Internet]. 2020 Oct [citado 25/02/2021];84:104493. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405773/. https://dx.doi.org/10.1016/j.meegid.2020.104493
5.Vargas-Lara AK, Schreiber-Vellnagel V, Ochoa-Hein E, López-Ávila A. SARS-CoV-2: una revisión bibliográfica de los temas más relevantes y evolución del conocimiento médico sobre la enfermedad. Neumol Cir Tórax [Internet]. 2020 Jul-Sep [citado 25/02/2021];79(3):185-196. Disponible en: https://www.medigraphic.com/pdfs/neumo/nt-2020/nt203k.pdf
6.Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol [Internet]. 2015 [citado 25/02/2021];1282:1-23. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369385/. https://dx.doi.org/10.1007/978-1-4939-2438-7_1
7.López Rodríguez CA, Boigues Pons M, Quirant Sánchez B, Teniente Serra A, Climent Martí J, Martínez Cáceres EM. SARS-CoV-2: una nueva amenaza. Avances Med Lab [Internet]. 2020 [citado 25/02/2021];1(4):20200045. Disponible en: https://www.degruyter.com/document/doi/10.1515/almed-2020-0045/html. https://doi.org/10.1515/almed-2020-0045
8.García A, García del Egido A, Murias E, Pérez S, Sánchez-Bayona R, Villacampa T. Coronavirus. Actualización enero 2021 [Internet]. España: Curso Intensivo MIR Asturias; 2021 [citado 25/02/2021]. Disponible en: https://www.docsity.com/es/curso-mir-astrurias-covid19/7208361/
9.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell [Internet]. 2020 Apr [citado 25/02/2021];181(2):271-280.e8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102627/. https://dx.doi.org/10.1016/j.cell.2020.02.052
10.Caravaca Pérez P, Morán Fernández L, García-Cosio MD, Delgado JF. Sistema renina-angiotensina-aldosterona y COVID19. Implicaciones clínicas. Rev Esp Cardiol Supl [Internet]. 2020 [citado 25/02/2021];20(E):27-32. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668217/. https://dx.doi.org/10.1016/S1131-3587(20)30032-7
11.Bio-Connect. Viral antigen bank by Sino Biological [Internet]. Netherlands: Bio-Connet; 02/09/2020 [citado 25/02/2021]. Disponible en: https://www.bio-connect.nl/news/viral-antigen-bank-by-sino-biological/
12.Organización Mundial de la Salud. Manejo clínico de la COVID-19. Orientaciones evolutivas, 25 de enero de 2021 [Internet]. Ginebra: OMS; 2021 [citado 25/02/2021]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/340629/WHO-2019-nCoV-clinical-2021.1-spa.pdf
13.van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med [Internet]. 2020 Apr [citado 25/02/2021];382(16):1564-1567. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7121658/. https://dx.doi.org/10.1056/NEJMc2004973
14.Arenas A, Cota W, Gómez-Gardeñes J, Gómez S, Granell C, Matamalas JT, et al. A mathematical model for the spatiotemporal epidemic spreading of COVID19. Medrxiv [Internet]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.03.21.20040022v1
15.Massachusetts General Hospital. Guía de control de infección de partners para transporte y movimiento de pacientes dentro del hospital con enfermedad respiratoria viral. Versión 1.0 27/03/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/Gu%C3%ADa-de-control-de-Infeccion-de%20Partners-para-Transporte%20y-Movimiento-de-Pacientes-Dentro-del-Hospital-con-Enfermedad-Respiratoria-Viral.pdf
16.Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimshaw A, Tal O, et al. Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol [Internet]. 2021 Jan [citado 25/02/2021];224(1):35-53.e3. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392880/. https://dx.doi.org/10.1016/j.ajog.2020.07.049
17.Centers for Diasease Control and Prevention. Public Health Guidance for Community-Related Exposure [Internet]. Atlanta: CDC; 01/03/2021 [citado 12/07/2021]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html
18.Centers for Diasease Control and Prevention. Public Health Guidance for Potential COVID-19 Exposure Associated with Travel [Internet]. Atlanta: CDC; 27/04/2021 [citado 12/07/2021]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html
19.Shah ASV, Wood R, Gribben C, Caldwell D, Bishop J, Weir A, et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ [Internet]. 2020 [citado 25/02/2021];371:m3582. Disponible en: https://www.bmj.com/content/371/bmj.m3582. https://doi.org/10.1136/bmj.m3582
20.Forbes H, Morton CE, Bacon S, McDonald HI, Minassian C, Brown JP, et al. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. BMJ [Internet]. 2021 [citado 12/07/2021];372:n628. Disponible en: https://www.bmj.com/content/372/bmj.n628. https://doi.org/10.1136/bmj.n628
21.Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant [Internet]. 2020 May [citado 25/02/2021];39(5):405-407. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118652/. https://dx.doi.org/10.1016/j.healun.2020.03.012
22.Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med [Internet]. 2020 May [citado 25/02/2021];172(9):577-582. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081172/. https://dx.doi.org/10.7326/M20-0504
23.Díaz E, Amézaga Menéndez R, Vidal Cortés P, Escapa MG, Suberviola B, Serrano Lázaro A, et al. Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH). Med Intensiva [Internet]. 2021 Mar [citado 12/07/2021];45(2):104–21. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833076/. https://dx.doi.org/10.1016/j.medine.2020.06.017
24.Victor Okhuese A. Estimation of the Probability of Reinfection With COVID-19 by the Susceptible-Exposed-Infectious-Removed-Undetectable-Susceptible Model. JMIR Public Health Surveill [Internet]. 2020 [citado 25/02/2021];6(2):e19097. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223428/. https://dx.doi.org/10.2196/19097
25.Yang Y, Yang M, Yuan J, Wang F, Wang Z, Li J, et al. Laboratory diagnosis and monitoring the viral shedding of SARS-CoV-2 infection. Innovation [Internet]. 2020 Nov [citado 25/02/2021];1(3):100661. Disponible en: https://www.sciencedirect.com/science/article/pii/S2666675820300643. https://doi.org/10.1016/j.xinn.2020.100061
26.Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. J Korean Med Sci [Internet]. 2020 May [citado 25/02/2021];35(18):e174. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211515/. https://dx.doi.org/10.3346/jkms.2020.35.e174
27.Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology [Internet]. 2020 Aug [citado 25/02/2021];296(2):E115-E117. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233365/. https://dx.doi.org/10.1148/radiol.2020200432
28.Complejo Hospitalario Universitario N/S La Candelaria (CHUNSC). Manejo clínico de la infección por SARS-CoV-2 (COVID-19) en adultos, según los diferentes escenarios clínicos en pacientes que ingresan en planta de hospitalización. 17/05/2021 Versión 8.8 [Internet]. Santa Cruz de Tenerife: Servicio Canario de la Salud; 2021 [citado 12/07/2021]. Disponible en: https://medicostenerife.es/wp-content/uploads/2020/10/Procedimiento2019-nCoV-SCS_9-29_09_20.pdf
29.Organización Mundial de la Salud. WHO COVID-19 Case definition. 16 de diciembre de 2020 [Internet]. Ginebra: OMS; 2020 [citado 25/02/2021]. Disponible en: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Surveillance_Case_Definition-2020.2
30.Massachusetts General Hospital. Estratificación de riesgo COVID-19. Versión 2.0 04/10/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/estratificacion-de-riesgo-covid.pdf
31.Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med [Internet]. 2020 May [citado 25/02/2021];18(1):206. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237880/. https://dx.doi.org/10.1186/s12967-020-02374-0
32.Wu YH, Li JY, Wang C, Zhang LM, Qiao H. The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke. J Clin Lab Anal [Internet]. 2017 [citado 25/02/2021];31(2):e22033. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817163/. https://dx.doi.org/10.1002/jcla.22033
33.Lu N, Yang Y, Wang Y, Liu Y, Fu G, Chen D, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep [Internet]. 2012 [citado 25/02/2021];39(6):6581-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22297693/. https://doi.org/10.1007/s11033-012-1487-1
34.López-Reyes A, Martinez-Armenta C, Espinosa-Velázquez R, Vázquez-Cárdenas P, Cruz-Ramos M, Palacios-Gonzalez B, et al. NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. Front Immunol [Internet]. 2020 Oct [citado 25/02/2021];11:570251. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662564/. https://dx.doi.org/10.3389/fimmu.2020.570251
35.Mayanga-Sausa SL, Guerra-Tueros RMS, Lira-Villasante DA, Pastor-Gutiérrez DK. Utilidad de la Radiografía de Tórax en el contexto de la pandema por SARS-CoV2. Rev Fac Med Hum [Internet]. 2020 Oct-Dic [citado 25/02/2021];20(4):682-89. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2308-05312020000400682. http://dx.doi.org/10.25176/rfmh.v20i4.3034
36.Massachusetts General Hospital. Guía de control de infecciones de partners para pacientes confirmados con COVID-19: Criterios para resolución del estatus de infección por COVID-19 y descontinuación del aislamiento. Versión 1.0 24/03/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guia-de-control-de-infecciones-partners-para-pacientes-confirmados-con-covid-19.pdf
37.Ministerio de Sanidad. Instituto de Salud Carlos III. Procedimiento de actuación frente a casos de infección por el nuevo coronavirus (SARS-CoV-2). Actualizado 31/03/2020 [Internet]. Madrid: Ministerio de Sanidad; 2020 [citado 25/02/2021]. Disponible en: https://www.semg.es/images/2020/Coronavirus/20200331_Procedimiento_actuacion_COVID_19.pdf
38.Centers for Diasease Control and Prevention. Investigative Criteria for Suspected Cases of SARS-CoV-2 Reinfection (ICR) [Internet]. Atlanta: CDC; 27/10/2020 [citado 25/02/2021]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html
39.Massachusetts General Hospital. Guía de manejo clínico para tratar pacientes críticos enfermos con COVID-19. Versión 2.0 04/05/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/Gu%C3%ADa-de-manejo-cl%C3%ADnico-para-tratar-pacientes%20cr%C3%ADticos.pdf
40.Nadar Llover M, Cols Jiménez M. Estado actual de los tratamientos para la COVID-19. FMC [Internet]. 2021 Jan [citado 25/02/2021];28(1):40-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826050/. https://dx.doi.org/10.1016/j.fmc.2020.10.005
41.Asociación de Neumología y Cirugía Torácica del Sur. Documento general COVID-19 [Internet]. Sevilla: NEUMOSUR; 2020 [citado 25/02/2021]. Disponible en: https://www.neumosur.net/files/noticias/2020/Coronavirus/Documentacio%CC%81n%20completa%20de%20Neumosur%20sobre%20COVID-19.pdf
42.Drahnak DM, Custer N. Prone Positioning of Patients with Acute Respiratory Distress Syndrome. Crit Care Nurse [Internet]. 2015 [citado 25/02/2021];35(6):29-37. https://pubmed.ncbi.nlm.nih.gov/26628543/. https://doi.org/10.4037/ccn2015753
43.Gutierrez Lopez A, Cruz Cardentey M, Mengana Betancourt A, Castañeda Chirino O, Martínez López F, Falcón Rodríguez R. Arritmias cardíacas en pacientes con la COVID-19. Escenarios y tratamiento. Rev Cuba Cardiol Cir Cardiovasc [Internet]. 2020 [citado 25/02/2021];26(3):e1006. Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/1006/pdf
44.Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA [Internet]. 2020 Apr [citado 25/02/2021];323(18):1824–1836. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2764727. https://doi.org/10.1001/jama.2020.6019
45.Ministerio de Salud Pública. Protocolo Nacional MINSAP vs COVID-19. 4 de abril de 2020 [Internet]. La Habana: MINSAP; 2020 [citado 25/02/2021]. Disponible en: https://covid19cubadata.github.io/protocolos/protocolo-version-2.pdf
46.Massachusetts General Hospital. Guía de monitoreo de QTC. Versión 1.0_04/01/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guia-de-monitoreo-de-QTC.pdf
47.Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation [Internet]. 2020 Apr [citado 25/02/2021];142(1):68-78. Disponible en: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047549. https://doi.org/10.1161/CIRCULATIONAHA.120.047549
48.Scholten EL, Beitler JR, Prisk GK, Malhotra A. Treatment of ARDS with prone positioning. Chest [Internet]. 2017 [citado 25/02/2021];151(1):215-224 Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026253/. https://dx.doi.org/10.1016/j.chest.2016.06.032
49.van de Veerdonk FL, Brüggemann RJM, Vos S, De Hertogh G, Wauters J, Reijers MHE, et al. COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respir Med [Internet]. 2021 July [citado 12/07/2021];9(7):795-802. Disponible en: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00138-7/fulltext. https://doi.org/10.1016/S2213-2600(21)00138-7
50.Massachusetts General Hospital. Preguntas frecuentes del manejo de pacientes con enfermedad COVID. Versión 1.0 04/01/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/preguntas-frequentes-sobre-la-guia-de-manejo-covid.pdf
51.National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. NICE Clinical Guidelines, No. 191 [Internet]. London: NICE; 2019 [citado 25/02/2021]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK552669/
52.Ministerio de Sanidad. Documento técnico. Manejo clínico del COVID-19: tratamiento médico, 19/03/2020 [Internet]. Madrid: Ministerio de Sanidad; 2020 [citado 25/02/2021]. Disponible en: https://www.semg.es/images/2020/Coronavirus/20200319_Protocolo_manejo_clinico_tto_COVID-19.pdf
53.Massachusetts General Hospital. Preguntas frecuentes del manejo de pacientes con enfermedad COVID. Versión 1.0 04/01/2020 [Internet]. Boston, Massachusetts: MGH; 2020 [citado 25/02/2021]. Disponible en: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/razonamiento-para-el-uso-de-estatinas.pdf
54.Veloz Ochoa X, Santillán Haro Á, Veloz Ochoa AB. Infección COVID-19 en adultos. InterAm J Med Health [Internet]. 2020 [citado 25/02/2021];3:e202003040. Disponible en: https://www.iajmh.com/iajmh/article/view/131/158. https://doi.org/10.31005/iajmh.v3i0.131
55.Hernández A, Papadakos PJ, Torres A, González DA, Vives M, Ferrando C, et al. Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por COVID-19. Rev Esp Anestesiol Reanim [Internet]. 2020 May [citado 25/02/2021];67(5):245-252. Dsponible en: https://www.elsevier.es/es-revista-revista-espanola-anestesiologia-reanimacion-344-articulo-dos-terapias-conocidas-podrian-ser-S003493562030075X. https://doi.org/10.1016/j.redar.2020.03.004
56.Servicios de Salud de San Luis Potosí. Ejercicios respiratorios para personas en recuperación de COVID-19 [Facebook]. 15/03/2021 [citado 12/07/2021]. Disponible en: https://www.facebook.com/ssaslp/photos/d41d8cd9/3974725375918223/
57.Organización Mundial de la Salud. Orientación internacional para la certificación y clasificación (codificación) del COVID-19 como causa de muerte. Basada en la CIE. Clasificación Estadística Internacional de Enfermedades. Ginebra: OMS; 2020.
58.Pinilla G, Cruz CA, Navarrete J. Diagnóstico molecular de SARS-CoV-2. NOVA [Internet]. 2020 [citado 25/02/2021];18(35):33-39. Disponible en: https://revistas.unicolmayor.edu.co/index.php/nova/article/view/1811/2684. https://doi.org/10.22490/24629448.4184
59.Morales Peralta E, Alvarez Fornaris MA. COVID-19: aspectos relacionados a la susceptibilidad genética y defectos congénitos. Rev Haban Cienc Méd [Internet]. 2020 [citado 25/02/2021];19(5):e3595. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2020000600004
60.Ramírez-Sagredo A, Ramírez-Reyes A, Paz Ocaranza M, Chiong M, Riquelme JA, Jalil JE, et al. Antihipertensivos en pacientes con COVID-19. Rev Chil Cardiol [Internet]. 2020 Abr [citado 25/02/2021];39(1):66-74. https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-85602020000100066. http://dx.doi.org/10.4067/S0718-85602020000100066
61.Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Chi-Chung Cheng V, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis [Internet]. 2020 Apr [citado 25/02/2021];ciaa478. Disponible en: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa478/5825667. https://doi.org/10.1093/cid/ciaa478
62.Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med [Internet]. 2020 Nov [citado 25/02/2021]:383(19):1827-1837. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/. https://dx.doi.org/10.1056/NEJMoa2015301
63.RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med [Internet]. 2021 Feb [citado 25/02/2021];384(8):693-704. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383595/. https://dx.doi.org/10.1056/NEJMoa2021436
64.Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. N Engl J Med [Internet]. 2020 Apr [citado 25/02/2021];383(1):85-88. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204427/. https://dx.doi.org/10.1056/NEJMc2009567
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
15 junio 2025
